Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05719714 · ClinicalTrials.gov registry record · Phase 1
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
A Phase 1 study of Heart Failure and Chronic Kidney Diseases, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05719714 is a Phase 1 study of Heart Failure and Chronic Kidney Diseases that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 60 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05719714, a Phase 1 study of Heart Failure and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Conditions Studied
Interventions
- DRUG Dapagliflozin 10 MG [Farxiga]
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05719714
The ClinicalTrials.gov registry entry for NCT05719714 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Dapagliflozin 10 MG [Farxiga] is the first listed.
NCT05719714 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05719714 about?
NCT05719714 is a clinical study titled "Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease". The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients...
What is the current status of trial NCT05719714?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-01-16. Estimated completion is 2026-09-30.
What conditions does trial NCT05719714 study?
This clinical trial studies the following conditions: Heart Failure, Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases.
What interventions are being tested in trial NCT05719714?
The interventions under investigation include: Dapagliflozin 10 MG [Farxiga] (DRUG).
Who is sponsoring clinical trial NCT05719714?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05719714 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.